Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators
A new series of RUNX3 modulators showed improved in vitro biological evaluations metabolic stability profiles. Compounds exhibited a significant in vivo antitumor activity and pharmacokinetic profiles. Compound 7k could be a highly potent and orally available anticancer agent.